PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAlitretinoin
Panretin(alitretinoin)
Panretin (alitretinoin) is a small molecule pharmaceutical. Alitretinoin was first approved as Panretin on 1999-02-02. It is used to treat kaposi sarcoma and skin diseases in the USA. It has been approved in Europe to treat kaposi sarcoma. The pharmaceutical is active against retinoic acid receptor beta, vitamin K epoxide reductase complex subunit 1, retinoic acid receptor gamma, and retinoic acid receptor alpha. In addition, it is known to target retinoic acid receptor RXR-beta, retinoic acid receptor RXR-gamma, and retinoic acid receptor RXR-alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Panretin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alitretinoin
Tradename
Company
Number
Date
Products
PANRETINADVANZ PHARMAN-020886 RX1999-02-02
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
panretinNew Drug Application2024-12-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
skin diseases—D012871L00-L99
kaposi sarcoma—D012514C46
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH04: Alitretinoin
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XF: Retinoids for cancer treatment
— L01XF02: Alitretinoin
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DermatitisD003872—L30.9——31—4
Atopic dermatitisD003876EFO_0000274L20———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EczemaD004485—L30.9—15——6
NeuroblastomaD009447EFO_0000621——12——3
Skin diseasesD012871—L00-L99——3——3
Hand dermatosesD006229————3——3
Breast neoplasmsD001943EFO_0003869C501—1——2
Male breast neoplasmsD018567————1——1
Lamellar ichthyosisD017490—Q80——1——1
IchthyosisD007057—E50.8——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver failureD017093—K72.911——12
Hepatic insufficiencyD048550——11——12
SarcomaD012509———1——12
Hiv infectionsD015658EFO_0000764B20—1——12
Kaposi sarcomaD012514—C46—1——12
LeukemiaD007938—C9511———1
Myelomonocytic leukemia juvenileD054429—C93.311———1
Lichen planusD008010—L43—1———1
Systemic lupus erythematosusD008180EFO_0002690M32—1———1
Cutaneous lupus erythematosusD008178EFO_0003834L93.1—1———1
Show 3 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlitretinoin
INNalitretinoin
Description
9-cis-retinoic acid is a retinoic acid in which the exocyclic double bonds have 7E,9Z,11E,13E geometry. It has a role as an antineoplastic agent, a retinoid X receptor agonist, a metabolite and a keratolytic drug. It is a conjugate acid of a 9-cis-retinoate.
Classification
Small molecule
Drug classretinol derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Identifiers
PDB—
CAS-ID5300-03-8
RxCUI—
ChEMBL IDCHEMBL705
ChEBI ID50648
PubChem CID449171
DrugBankDB00523
UNII ID1UA8E65KDZ (ChemIDplus, GSRS)
Target
Agency Approved
RARB
RARB
Organism
Homo sapiens
Gene name
RARB
Gene synonyms
HAP, NR1B2
NCBI Gene ID
Protein name
retinoic acid receptor beta
Protein synonyms
HBV-activated protein, hepatitis B virus activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-beta, RAR-epsilon, retinoic acid receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Rarb (218772)
retinoic acid receptor beta (P22605)
Alternate
RXRG
RXRG
RXRB
RXRB
Organism
Homo sapiens
Gene name
RXRG
Gene synonyms
NR2B3
NCBI Gene ID
Protein name
retinoic acid receptor RXR-gamma
Protein synonyms
Nuclear receptor subfamily 2 group B member 3, Retinoid X receptor gamma
Uniprot ID
Mouse ortholog
Rxrg (20183)
retinoic acid receptor RXR-gamma (P28705)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 840 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
93 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use